International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer

Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels of excision repair...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2022-01, Vol.33 (1), p.57-66
Hauptverfasser:	Novello, S., Torri, V., Grohe, C., Kurz, S., Serke, M., Wehler, T., Meyer, A., Ladage, D., Geissler, M., Colantonio, I., Cauchi, C., Stoelben, E., Ceribelli, A., Kropf-Sanchen, C., Valmadre, G., Borra, G., Schena, M., Morabito, A., Santo, A., Gregorc, V., Chiari, R., Reck, M., Schmid-Bindert, G., Folprecht, G., Griesinger, F., Follador, A., Pedrazzoli, P., Bearz, A., Caffo, O., Dickgreber, N.J., Irtelli, L., Wiest, G., Monica, V., Porcu, L., Manegold, C., Scagliotti, G.V.
Format:	Artikel
Sprache:	eng
Schlagworte:	adjuvant chemotherapy Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy, Adjuvant excision repair cross-complementation 1 Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - surgery messenger RNA Neoplasm Staging non-small-cell lung cancer Pharmacogenetics pharmacogenomics thymidylate synthase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!